PRINCETON, N.J., July 9 (Bernama-GLOBE NEWSWIRE) — SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it has received its sixth ANDA approval from the US Food and Drug Administration (FDA).
The sixth approved ANDA is for Methylprednisolone tablets, 4 mg. This drug product is a corticosteroid used to treat conditions including arthritis, allergic reactions, and immune system disorders, as well as dermatologic, ophthalmic, respiratory, and gastrointestinal diseases. Methylprednisolone tablets had total U.S. sales of $93 million for Q1 of 2019, and $113 million and $124 million, respectively, for 2018 and 2017 according to IQVIA.
